Multaq Articles
FDA strengthens warnings on Sanofi’s Multaq; Aubagio disappoints
20 December 2011
EMA recommends restricting use of Sanofi AF drug Multaq, but sees positive benefit-risk in some patients
23 September 2011
US FDA now joins in probe of Sanofi’s Multaq safety
25 July 2011
Brazil patent office scores victory over Multaq case
13 July 2011
Mixed Ph III results for Sanofi MS drug candidate Lemtrada; EMA to broaden review of Multaq
12 July 2011
CV events halt Sanofi Multaq trial; Merck KGaA drops Idera cancer drug on safety concerns
8 July 2011
EMA advisory committee backs Gilenya, Halaven, Jevtana, Pravafenix and Trobalt, but negatives for Fampyra and Multaq
24 January 2011
US FDA warns on acute liver failure with Sanofi-Aventis Multaq
17 January 2011
Highlights of ESC include strong data on AstraZeneca’s Brilinta and Servier’s Procoralan; ESC guideline for atrial fibrillation
31 August 2010
Draft guidance from UK’s NICE recommends Celgene and Janssen Cilag multiple myeloma drugs; Sanofi-Aventis’ Multaq approved for AF
27 August 2010
Sanofi-Aventis 2009 EPS leaps 18% but slows in 4th quarter; in line with expectations
10 February 2010
Draft guidance from UK’s NICE unable to recommend Sanofi-Aventis’ Multaq for atrial fibrillation
24 December 2009
Atrial fibrillation drug market to grow more than sevenfold, to $6.1 billion in 2018
16 December 2009
Sanofi-Aventis to reinforce its presence in Russia via the ”Pharmpolis Project;” Multaq approved by EC
30 November 2009
Sanofi Aventis' Multaq recommended for approval in the EU
28 September 2009
FDA panel gives nod to Sanofi's Multaq
23 March 2009
Chris Viehbacher takes over at Sanofi-Aventis
8 December 2008
Sanofi presents ATHENA trial results at AHA
17 November 2008
Sanofi publishes new data on Multaq
8 September 2008
Sanofi's Multaq gets FDA priority review
18 August 2008
Multaq reduces severe CV complications 24%
2 June 2008
Correction: Sanofi-Aventis' dronedarone
5 December 2005
Correction: Sanofi-Aventis' dronedarone
5 December 2005
Showing 1-31 of 31 articles
- 1
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
